← Back to Screener
Taysha Gene Therapies, Inc. Common Stock (TSHA)
Price$5.97
Value ScoreF
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)31.19%
Price vs S&P 500 (4W)-12.24%
VGM Score54.70
Market Capitalization$1.69B
All Metrics
Book Value / Share (Quarterly)$0.74
P/TBV (Annual)342.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)57.53%
Cash Flow / Share (Quarterly)$-0.39
Price vs S&P 500 (YTD)-4.21%
Net Profit Margin (TTM)-780.33%
EPS (TTM)$-0.38
10-Day Avg Trading Volume2.34M
EPS Excl Extra (TTM)$-0.38
EPS (Annual)$-0.34
ROI (Annual)-36.65%
Cash / Share (Quarterly)$0.96
Revenue Growth QoQ (YoY)171.27%
ROA (Last FY)-31.75%
Revenue Growth TTM (YoY)3.42%
EBITD / Share (TTM)$-0.38
ROE (5Y Avg)-3789.27%
Operating Margin (TTM)-782.50%
Cash Flow / Share (Annual)$-0.33
P/B Ratio7.96x
P/B Ratio (Quarterly)6.06x
Net Income / Employee (Annual)$-1,101,000
EV / Revenue (TTM)149.34x
Net Interest Coverage (TTM)-77.24x
ROA (TTM)-40.16%
EPS Incl Extra (Annual)$-0.34
Current Ratio (Annual)12.23x
Quick Ratio (Quarterly)13.84x
3-Month Avg Trading Volume2.66M
52-Week Price Return113.45%
Revenue / Employee (TTM)$75,500
Tangible BV / Share (Quarterly)$-0.26
P/S Ratio (Annual)172.60x
Asset Turnover (Annual)0.03x
52-Week High$7.30
EPS Excl Extra (Annual)$-0.34
CapEx CAGR (5Y)55.95%
26-Week Price Return47.12%
Quick Ratio (Annual)12.10x
13-Week Price Return28.45%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)14.04x
Enterprise Value$1.46B
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-34.68%
Revenue / Employee (Annual)$98,700
Pretax Margin (Annual)-1115.27%
Cash / Share (Annual)$1.12
3-Month Return Std Dev83.22%
Net Income / Employee (TTM)$-1,311,900
ROE (Last FY)-44.14%
Net Interest Coverage (Annual)-65.37x
EPS Basic Excl Extra (Annual)$-0.34
Total Debt / Equity (Quarterly)0.23x
EPS Incl Extra (TTM)$-0.38
ROI (TTM)-46.41%
P/S Ratio (TTM)172.60x
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.02
Price vs S&P 500 (52W)85.25%
Year-to-Date Return6.73%
5-Day Price Return6.92%
EPS Normalized (Annual)$-0.34
ROA (5Y Avg)-73.00%
Net Profit Margin (Annual)-1115.27%
Month-to-Date Return-8.14%
Cash Flow / Share (TTM)$-2.76
EBITD / Share (Annual)$-0.34
Operating Margin (Annual)-1130.65%
LT Debt / Equity (Annual)0.20x
ROI (5Y Avg)-153.51%
LT Debt / Equity (Quarterly)0.23x
EPS Basic Excl Extra (TTM)$-0.38
P/B Ratio (Annual)6.10x
Pretax Margin (TTM)-780.33%
Book Value / Share (Annual)$0.87
Price vs S&P 500 (13W)18.70%
Beta1.25x
Revenue / Share (TTM)$0.02
ROE (TTM)-56.07%
52-Week Low$2.25
vGradeF
gGradeB
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.12est. -0.10
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TSHATaysha Gene Therapies, Inc. Common Stock | F | B | A | $5.97 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Taysha Gene Therapies develops AAV-based gene therapies for monogenic central nervous system diseases, targeting both rare and large patient populations. Its clinical-stage pipeline includes TSHA-102, a self-complementary AAV9 therapy delivered intrathecally for the treatment of Rett syndrome.